B. Esteves

Joint statement on evidence-based practices in mechanical ventilation: suggestions from two Brazilian medical societies

Juliana Carvalho Ferreira, Arthur Vianna, Bruno Valle Pinheiro, Israel Silva Maia et autres

Mechanical ventilation can be a life-saving intervention, but its implementation requires a multidisciplinary approach, with an understanding of its indications and contraindications due to the potential for complications. The management of mechanical ventilation should be part of the curricula during clinical training; …

br, au (code pays fourni par la source)

Analgesic Effect of Sulforaphane: A New Application for Poloxamer-Hyaluronic Acid Hydrogels

Juliana Zampoli Boava Papini, B. Esteves, Vagner Gomes de Souza Oliveira, Henrique Ballassani Abdalla et autres

Sulforaphane (SFN) has shown potential as an antioxidant and anti-inflammatory agent. To improve its druggability, we developed new analgesic formulations with sulforaphane-loaded hyaluronic acid (HA)-poloxamer (PL) hydrogel. This study evaluated the pre-clinical safety and effectiveness of these formulations. Effectiveness was tested on …

br (code pays fourni par la source)

OUTCOMES OF SEPTAL REDUCTION THERAPY IN A NEWLY ESTABLISHED MULTIDISCIPLINARY HYPERTROPHIC CARDIOMYOPATHY PROGRAM: THE BRITISH COLUMBIA EXPERIENCE

A. Husain, F. Alajmi, N Hähn, B. Esteves et autres

OUTCOMES OF SEPTAL REDUCTION THERAPY IN A NEWLY ESTABLISHED MULTIDISCIPLINARY HYPERTROPHIC CARDIOMYOPATHY PROGRAM: THE BRITISH COLUMBIA EXPERIENCE

A. Husain, F. Alajmi, N Hähn, B. Esteves et autres

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

K.N. Moore, D. Lorusso, Ana Oaknin, Sandro Pignata et autres

us, it, es, be, de, ie (code pays fourni par la source)

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

U. Matulonis, Katherine Moore, Domenica Lorusso, Ana Oaknin et autres

us, it, es, be, de, ie (code pays fourni par la source)

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

Mayer Fishman, S. Srinivas, Ralph J. Hauke, R. J. Amato et autres

us (code pays fourni par la source)

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Robert J. Motzer, D. Nosov, Tim Eisen, Oleg Lipatov et autres

P040 Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)

Dmitry Nosov, Robert J. Motzer, John W. Loewy, Lucy S. Hodge et autres

Tivozanib Pharmacokinetic (PK)/Pharmacodynamic (PD) Analysis of Blood Pressure (BP) and Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) in Patients with Advanced Renal Cell Carcinoma (RCC)

D. Nosov, Robert J. Motzer, John W. Loewy, Lucy S. Hodge et autres

ru, us (code pays fourni par la source)

Detailed Comparison of the Safety of Tivozanib Versus Sorafenib in Patients with Advanced/Metastatic Renal Cell Carcinoma (MRCC) from a Phase 3 Trial

Tim Eisen, Cora N. Sternberg, Piotr Tomczak, M. Hârza et autres

A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).

Fairooz F. Kabbinavar, S. Srinivas, Ralph J. Hauke, R. J. Amato et autres

330 Background: Tivozanib, a potent and selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, has demonstrated antitumor activity in a phase II study in RCC (Proceedings of ASCO 2009, Abstract 5032). Temsirolimus, a mammalian target …

us (code pays fourni par la source)